Treatment of Hepatitis C With the Earliest Protease Inhibitor-Based Therapy

被引：0
|
作者：
Smith, Zohreh Movahedi [1 ]
Brussman, Keith [1 ]
Nadir, Abdul [1 ]
机构：
[1] Maricopa Cty Gen Hosp, Phoenix, AZ 85008 USA
来源：
MAYO CLINIC PROCEEDINGS | 2014年 / 89卷 / 09期
关键词：
TRIPLE THERAPY; GENOTYPE;
D O I：
10.1016/j.mayocp.2014.06.020
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1319 / 1320
页数：3
相关论文
共 50 条
  • [31] Hepatitis C protease inhibitor
    不详
    CHEMICAL & ENGINEERING NEWS, 2003, 81 (44) : 34 - 34
  • [32] IMPROVEMENT OF ADVANCED LIVER FIBROSIS AND REGRESSION OF LIVER CIRRHOSIS IN PATIENTS WITH HEPATITIS C GENOTYPE 1 AFTER HCV PROTEASE INHIBITOR-BASED TRIPLE THERAPY
    Saez-Royuela, F.
    Linares, P.
    Cervera, L. A.
    Almohalla, C.
    Jorquera, F.
    Garcia, I.
    Moncada, A.
    Karpman, G.
    Badia, E.
    Vallecillo, M. A. A.
    Lorenzo, S.
    Olcoz, J. L.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S594 - S594
  • [33] Protease inhibitor therapy for hepatitis C virus-infection
    de Leuw, P.
    Stephan, C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (06) : 577 - 587
  • [34] Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy
    Goicoechea, Miguel
    Liu, Shanshan
    Best, Brookie
    Sun, Shelly
    Jain, Sonia
    Kemper, Carol
    Witt, Mallory
    Diamond, Catherine
    Haubrich, Richard
    Louie, Stan
    JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (01): : 102 - 108
  • [35] Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme
    Wood, E.
    Hogg, R. S.
    Yip, B.
    Moore, D.
    Harrigan, P. R.
    Montaner, J. S. G.
    HIV MEDICINE, 2007, 8 (02) : 80 - 85
  • [36] Hepatitis C Patient Management Issues in the Era of Protease Inhibitor Based Triple Therapy
    Palmer, Melissa
    PRACTICAL GASTROENTEROLOGY, 2012, 36 (04) : 33 - 46
  • [37] In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy
    Ananworanich, J
    Nuesch, R
    Teeratakulpisam, S
    Srasuebkul, P
    Chuenyam, T
    Siangphoe, U
    Ungsedhaphand, C
    Phanuphak, P
    Ruxrungtham, K
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (05) : 570 - 572
  • [38] Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy
    Suaysod, Rapeepan
    Ngo-Giang-Huong, Nicole
    Salvadori, Nicolas
    Cressey, Tim R.
    Kanjanavanit, Suparat
    Techakunakorn, Pornchai
    Krikajornkitti, Sawitree
    Srirojana, Sakulrat
    Laomanit, Laddawan
    Chalermpantmetagul, Suwalai
    Lallemant, Marc
    Le Coeur, Sophie
    McIntosh, Kenneth
    Traisathit, Patrinee
    Jourdain, Gonzague
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (01) : 95 - 101
  • [39] Two Years' Persistence of Naturally Present Substitution R155K Within Hepatitis C Virus NS3 Protease in the Absence of Protease Inhibitor-based Therapy
    Colson, Philippe
    Gerolami, Rene
    JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (09): : 1341 - 1341
  • [40] Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy
    Brayer, Samuel W.
    Reddy, K. Rajender
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (05) : 547 - 558
12345